IBRX FY 2025 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$113M+668.3% YoY

Gross Profit

$113M99.3% margin

Operating Income

-$256M-226.0% margin

Net Income

-$351M-310.2% margin

EPS (Diluted)

$-0.38

Cash Flow

Operating Cash Flow

-$305M

Free Cash Flow

-$305M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$502M

Total Liabilities

$1.0B

Stockholders' Equity

-$500M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$113M	$15M	+668.3%
Gross Profit	$113M	$15M	+663.2%
Operating Income	-$256M	-$344M	+25.6%
Net Income	-$351M	-$414M	+15.0%